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It is becoming increasingly common for cardiologists to become
involved with the pharmaceutical industry and device manufac-
turers. Our faculty and our graduating fellows are almost as likely
to consider job opportunities in industry as they are to consider
more traditional academic or practice positions. Cardiologist-
entrepreneurs are becoming increasingly common and thus serve
as role models for fellows coming through our training programs.
This new breed of cardiologist is now beset with ethical issues
engendered by real or perceived conflicts of interest, especially as
they relate to CME talks or research studies. In its simplest form,
conflict of interest is personal gain associated with promoting a
product in which a person has a financial interest.
This ethical dilemma was highlighted by a New York Times
article (1) that detailed the financial conflicts of interest of
several prominent interventional cardiologists. In discussing
the effects of the conflict of interest on reporting the results of
trials, the article said: “. . . Financial ties have transformed the
traditional system of objective medical research and review.
Now the system used to determine which device is best for
heart patients can be influenced as much by personal financial
interests as by scientific data” (1). The article goes on to decry
the lack of oversight and the failure to voluntarily disclose such
conflicts. The tone of the article is such that it appears to the
reader that conflicts of interest are the norm for interventional
cardiologists, especially leaders in the field.
There are, of course, reasonable arguments to support the
importance of a business relationship between physicians and
industry. In a free market economy fueled by new ideas, we
generally applaud those individuals who succeed in business by
developing innovative and useful products. In Silicon Valley,
just south of San Francisco, there is a burgeoning number of
small computer or internet startup companies and a healthy
number of 30-year-old millionaires. Our daughter works for
such a company. We are not surprised if the CEO of such a
company enthusiastically describes the merits of its software,
web-based business, or whatever. In the business relationships
formed in medicine, however, things are different. When
physician experts serve as consultants, etc., to industry, they are
in a unique position to influence other physicians by virtue of
their roles as physician educators and researchers. Is it right, for
example, for the inventor/developer of a product to be a
principal investigator on a pivotal trial? How the data are
collected, analyzed, and reported can pose an enormous con-
flict of interest. A more favorable spin on the data may lead to
important economic returns to the physician.
Personally, I think that it is important for a physician/
developer to be intimately involved in the early clinical expe-
rience of a device, where modification of the device may be
important. However, it also seems to me that this same
physician should dissociate himself/herself from pivotal trials
and that those should be carried out in an unbiased way by
other groups with appropriate committees and safeguards.
Many universities, including ours, have a conflict-of-interest
committee that reviews such issues. Although such a review
costs time and paperwork, it is an important ethical safeguard.
Another potent tool for defusing conflict of interest is full
disclosure. At JACC, we require this from all authors (and
reviewers). We avoid conflicts of interest with authors from our
own institution by sending such papers out to a guest editor
who independently gets reviews and makes decisions. The
process of voluntary self disclosure works reasonably well for
scientific papers, but it appears to be less effective at national
meetings (despite the identification in the program of such a
presenter with an asterisk) and is almost nonexistent at other
conferences and CME meetings.
Even though it may not currently be succeeding well, full
disclosure remains a powerful tool for helping the audience to
judge the impartiality of any scientific presentation. It seems to
me that an initial slide (perhaps right after a title slide) should
be used routinely to disclose conflicts of interest. For each
company listed, the relationship should be clearly stated—e.g.,
officer, stockholder, speaker’s bureau, consultant, funding for
the study, etc. If all speakers routinely use such a slide, I believe
it would greatly help the audience and greatly defuse any
conflict of interest. If such a slide is not available, then the
potential conflicts of interest should be stated verbally. I
believe, however, that the routine use of a conflict-of-interest
slide before every presentation would be an important step in
the right direction. If this were widely adopted, I believe it
would go a long way toward defusing the negative impact of
conflict of interest. I welcome your comments on this impor-
tant and timely topic.
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